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SUMMARY
We present a systems strategy that facilitated the development of a molecular signature for 
glioblastoma (GBM), composed of 33 cell-surface transmembrane proteins. This molecular 
signature, GBMSig was developed through the integration of cell-surface proteomics and 
transcriptomics from patient tumors in the REMBRANDT (n=228) and TCGA datasets (n=547) 
and can separate GBM patients from controls with an MCC value of 0.87 in a lock-down-test. 
Functionally, 17/33 GBMSig proteins are associated with TGFβ signaling pathways, including: 
CD47, SLC16A1, HMOX1 and MRC2. Knockdown of these genes impaired GBM invasion, 
reflecting their role in disease-perturbed changes in GBM. ELISA assays for a subset of GBMSig 
(CD44, VCAM1, HMOX1, and BIGH3) on 84 plasma specimens from multiple clinical sites 
revealed a high degree of separation of GBM patients from healthy controls (AUC 0.98 in ROC). 
Additionally, a classifier based on these four proteins differentiated the blood of pre- and post-
tumor resections, demonstrating potential clinical value as biomarkers.
eTOC Blurb
Multidimensional analysis of GBM cell-surface proteins reveals a disrupted membrane-signaling 
network that can be identified from the blood of GBM patients, a subset of which can distinguish 
between normal and diseased individuals.
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A systems approach that integrates multi-omic measurements offers an avenue for better 
understanding the emergent properties and complexities of a disease process. Considering 
the recent advancements in omics technologies and machine learning, the power of a 
systems approach, in contrast to the single parameter atomistic approach, can enable the 
development of molecular signatures for complex diseases such as cancer (Sung et al., 
2012). However, such an approach that integrates data types across multiple sources also 
needs empirical validation since the separation of true disease signal from noise that arises 
out of variability in omics platforms-both biological and technical is essential. Here we have 
attempted to develop such a molecular signature for glioblastoma (GBM) through the 
integration of high-resolution proteomics and transcriptomics supported by end-to-end 
experimental validation.
Despite significant improvements in treatment and survival outcomes for other cancers, the 
median survival rate for GBM with treatment is still only 15 months—a figure that has been 
largely unchanged for decades (Demuth T, 2004; Mrugala, 2013; Delyon et al., 2015; 
Grabowski and Sehouli, 2015; Jorgensen and Knudtson, 2015; Limani et al., 2015; Milroy, 
2015; Rollig et al., 2015). MRI scans are used to diagnose or evaluate tumor progression, but 
these studies are often difficult to interpret due to variability in the appearance of the tumor 
and include a degree of subjectivity (Thompson et al., 2011). The field of neurooncology 
would benefit from a blood-based molecular signature of GBM that could complement MRI 
scans and existing genomic tests (Hegi and Stupp, 2013; Kurscheid et al., 2015; Murat et al., 
2008; Stupp et al., 2006).
Most attempts at developing robust biomarkers have failed to make it to the clinic (Omenn et 
al., 2012; Sung et al., 2012), and there is a process of validation that must be followed to 
generate a robust molecular signature appropriate for clinical use. That is not what we will 
present herein – that will be a subsequent downstream evaluation. Rather, here we have 
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focused on the development of a molecular signature, GBMSig, which defines the set of 
transmembrane proteins whose transcript concentrations are perturbed in GBMs compared 
to healthy control tissues and on identifying the extent to which some of these have been 
released into the blood and can be observed by targeted mass spectrometry.
Cell-surface transmembrane proteins occupy a strategic location between the cell and its 
microenvironment, and can propagate signals from both exofacial and cytoplasmic ends of 
the membrane (Chen et al., 2008; De Marco et al., 2013; Kandouz, 2012; Murai and 
Pasquale, 2010; Pasquale, 2010). Since aberrant expression of these proteins on the cell-
surface is known to disrupt normal cell activities and influence neoplastic transformation 
(Okumura et al., 2004; Teh and Chen, 2012), we hypothesized that integration of 
transcriptomic and proteomic expression data for these proteins would enrich for putative 
targets that could be the basis for a molecular GBM signature with a higher probability of 
being mechanistically linked to the underlying pathology. Cell-surface transmembrane 
proteins are often cleaved and shed into the blood in pathological conditions, making them 
ideal targets for diagnostic blood markers (Li et al., 2013; Shao et al., 2012; Varady et al., 
2013).
Cell-surface-transmembrane proteins tend to be low-abundant in the blood and are the 
proverbial needles in the haystack, presenting significant challenges in their detection even 
after depletion of highly abundant proteins. Reproducible quantification of these low 
abundant proteins can only be achieved after they have been identified. To first identify 
candidate tumor-derived, cell-surface transmembrane proteins, we performed comparative 
cell-surface proteomics analyses of four relevant GBM cell lines: CD133+ cancer stem cells, 
healthy neural stem cells, as well as the GBM cell lines U87MG and T98. Considering the 
possibility that the protein expression profile could be altered for a variety of reasons, 
including in-vitro culturing (Ertel et al., 2006; Vogel et al., 2005), we integrated cell-surface 
proteomics data with primary GBM tissue transcriptomic compendia of the REMBRANDT 
and TCGA. This integrative approach (Figure 1) helped us to verify mRNA expression of 
corresponding proteins identified through shotgun proteomics and also to develop a robust, 
GBM-specific membrane signature (GBMSig) composed of 33 proteins that reflects the 
biology of GBM with potential for tissue and blood-based diagnosis.
RESULTS
Compositional analysis of GBM cell-surface proteome by shotgun proteomics
There is significant heterogeneity across tumors of individuals, even within each of the four 
molecular subtypes. To capture some of this heterogeneity, we performed cell-surface 
proteomics on four cell lines including two GBM cell lines UMG87 and T98, a GBM cancer 
stem cell line (grown at the source, Celprogen, that ensured CD133 expression) and a 
healthy neural stem cell line (positive for putative stem cell markers tub iii, oct-4, sox-2, and 
nestin from Millipore). Cell-surface proteins were labeled and captured with membrane-
impermeable sulfo-NHS-SS-biotin from intact cells (Figure S1).
Captured cell-surface proteins were subjected to high-resolution mass spectrometry in 
triplicate (technical replicates) and the proteins were identified using the Global Proteome 
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Machine [(the GPM) (http://www.theGPM.org)] with minimum log expectation scores of 
<10−3 (Craig and Beavis, 2003, 2004; Fenyo et al., 2007; Ghosh et al., 2010). We identified 
a total of 868, 813, 541, and 564 non-redundant proteins from U87MG, T98, neural stem 
cell, and cancer stem cell populations, respectively (Figure 2A–D and Table S1). While our 
experimental approach was designed to enrich for cell-surface proteins, we also employed 
the transmembrane prediction algorithm TMHMM (Krogh et al., 2001; Moller et al., 2001) 
to identify those cell-surface proteins with transmembrane domains from the total identified 
proteins. Although this filtering step was rather strict and likely eliminated several true 
positives, we were left with 157, 154, 98, and 80 cell-surface transmembrane proteins in 
U87MG, T98, neural stem cell, and cancer stem cell lines, respectively. Overall 274 different 
cell-surface transmembrane proteins were identified from all four cell lines. Among cell-
surface transmembrane proteins identified, we found 53 cluster-of-differentiation (CD) 
markers, which in general offer an immunological basis for separating different cell types 
(Beare et al., 2008; Erber, 1990).
We also identified 98 multi-transmembrane domain containing cell-surface proteins, which 
are underrepresented in whole-cell proteomic datasets because of their hydrophobicity and 
limited cellular abundance. As would be expected, functional classification of these proteins 
highlighted the enrichment of those biological processes that are known to be associated 
with cell-surface activities such as cell adhesion and migration, transport, and bi-directional 
signaling (Figure 2E–F). We also observed a difference in enrichment of immune regulatory 
processes among all three distinct cancer cell lines (U87MG, T98, and cancer stem cell line) 
compared to the healthy neural stem cells—reflective of the functional differences between 
these cell types (Table S1). Our cell-surface proteome analysis identified transmembrane 
proteins expressed among various GBM cell lines related to different aspects of GBM 
biology. This approach provided us with a list of proteomic targets that, upon further 
selection based on RNA expression (described below), were good candidates for detection 
and measurement by quantitative selected reaction monitoring (SRM) mass spectrometry. 
The XML data files are available for viewing at http://human.thegpm.org/tandem/
thegpm_upview.html. Unique Global Proteome Machine IDs for proteins identified in each 
cell line are provided in the key resources table of STAR Method section of this paper.
Differentially expressed cell-surface transmembrane proteins in GBM
For a candidate list of differentially expressed transcripts between tumor and non-tumor 
regions of the brain, we utilized microarray data from the REMBRANDT tissue source 
(http://rembrandt.nci.nih.gov). Out of 274 cell-surface transmembrane proteins identified 
from the proteomics study, we found expression data for 202 (532 independent probes) 
corresponding transcripts in REMBRANDT. Expression levels in the tumor transcriptomes 
were, on average, much more abundant than those from their normal counterparts, possibly 
as an artifact of the small number of available normal control samples, but also likely due to 
a real difference in transcript expression. Because of the small number of control samples, 
we used a conservative cutoff of two-fold average expression change with FDR<0.05. 
Among the resulting 202 selected transcripts, we observed 155 of them were upregulated 
and 47 were down-regulated (Figure 3A). To identify GBM-specific cell-surface 
transmembrane protein expression changes, we filtered out transcripts found to be 
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differentially expressed in non-GBM brain diseases such as astrocytoma (N=148 tumors) 
and oligodendroma (N=67 tumors) relative to the same REMBRANDT control samples. 
This filtering approach further reduced the number of candidate cell-surface transmembrane 
proteins from 202 to 33 (Figure 3A–F and Figure S2).
To increase confidence that these 33 candidate proteins could represent real differences 
between case and control samples, we tested their performance as a GBM signature 
(designated as GBMSig) in an independent dataset: TCGA (The Cancer Genome Atlas, 
2008) (N=547 GBM tumor samples and 10 healthy brain tissues). We designed a Support 
Vector Machine (SVM) classifier (C. Cortes and Vapnik, 1995) with parameters tuned in 10-
fold cross validation on the REMBRADT training set (Figure S2A). We then classified the 
TCGA test set with a lock-down test (Figure S2B). We obtained a Mathew’s correlation 
coefficient (MCC) of 0.87, exhibiting 99% positive predictive value and 89% negative 
predictive value for our classifier. Of note, while the high predictive values for both 
REMBRANDT and TCGA should be evaluated in the light of the disproportionately small 
control samples, the purpose of this step was to evaluate the robustness of the targets 
following integration of the proteomic and transcriptomic datasets and thus this 
transcriptomic step was a means for helping to select the protein signature (GBMSig) 
presented herein and not an end in and of itself.
Principal component analysis (PCA) of the GBMSig genes and individual specificities and 
sensitivities from ROC analyses of training and validation set (TCGA) are presented in 
Figures 3C–3F and Table S2 respectively. Taken together, these results support the predictive 
power of the 33 protein GBMSig classifier and suggest that the integration of both 
proteomic and transcriptomic data and stringent filtering have enriched for candidate 
proteins of interest that might be quantitatively different in their expression between GBM 
and control patients.
Quantitative SRM assays for GBMSig
As an initial step to evaluating a subset of GBMSig as biomarkers in the blood, we 
developed quantitative SRM assays for all 33 proteins (Li et al., 2013; Picotti and Aebersold, 
2012;Bereman et al., 2012). Our earlier cell-surface protein profiling of GBM cell lines 
provided data for selecting mass spectrometry compatible peptides with appropriate mass to 
charge ratios (m/z). Seventy cell-surface protein peptide representatives from 33 GBMSig 
proteins were generated for SRM assay development—approximately 2 for each protein. 
Synthetic peptides labeled (13C15N) C-terminally with either lysine (K) or arginine (R) act 
as surrogates of endogenous peptides. These peptides were subjected to collision energy 
(CE) optimization (Maclean et al., 2010) to maximize the release of trapped energy from 
each peptide bond. Three parental (Q1) charges (+2, +3, and +4) and two daughter (Q3) ion 
charges (+1 and +2) of peptides were tested in all feasible combinations for assay 
optimization; the Q1/Q3 transition-CE combination that demonstrated the highest SRM 
peak-intensity and was minimally affected by interfering ions was selected for assay 
validation (Table S3). In the final SRM assay, the best performing peptide with a minimum 
of three transitions was used for quantitation. Retention time of each surrogate peptide was 
determined empirically, which helped to develop dynamic-SRM assays (d-SRM). This 
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targeted approach improved the sensitivity and specificity, enabling the reproducible 
measurement of low abundant GBMSig proteins in complex bio-specimens. Four resected 
GBM tumors and two non-tumor brain tissue samples were homogenized, enzymatically 
digested, clarified using C18, and spiked with synthetic C-terminally labeled (13C15N K/R) 
peptides for subsequent SRM mass spectrometry analysis (three technical replicates). Of the 
33 GBMSig proteins assayed we were able to reliably detect 21 across all samples. Twelve 
of the 21 GBMSig proteins were overexpressed in all four GBM tissues relative to non-
tumor brain tissues. The list of these proteins including nine proteins with p<0.05 are 
presented in Table S4. Protein expression data and PCA analyses are represented in Figure 
4A–C. Although a majority of GBMSig proteins (12 of 21) revealed differential expression 
between tumor and non-tumor regions of the brain, intratumor heterogeneities in GBMSig 
expression as investigated through tumor subtyping (Phillips et al., 2006) underscored the 
nature of combinatorial perturbation of membrane networks across different clinical 
specimens (Figure 4D, Table-S4–5).
Utility of GBMSig in the assessment of tumor progression and diagnosis through blood 
analysis
Cell-surface proteins are known to be secreted or shed into the blood stream by both healthy 
and tumor cells and the concentration changes in those proteins from tumor cells (as 
compared to normal cells) reflect the fact that their cognate networks have become perturbed 
(Li et al., 2013; Shao et al., 2012). As would be expected, given our initial decision to select 
for cell-surface proteins, we found twenty-one of 33 GBMSig proteins to possess N-terminal 
secretion signal sequences (SignalP4.1, www.cbs.dtu.dk). However, protein secretion in the 
blood is a complex process and can be controlled by a multitude of factors (Uhlen et al., 
2015). Therefore, we sought to identify which GBMSig proteins could be identified in the 
blood of GBM patients through empirical means. In a pilot study, we evaluated four GBM 
plasmas (pre-operative blood collection) for circulating GBMSig proteins by SRM mass 
spectrometry (Table S6). Following immunodepletion of the 14 most abundant blood 
proteins, we detected 14 of 33 GBMSig proteins independently in triplicate SRM runs 
(Table S6). Four circulating GBMSig proteins (HMOX1, CD44, VCAM1, and BIGH3 
(TGFBI)) were selected for further evaluation by ELISA assays for potential GBM diagnosis 
based on 1) detection by SRM in the blood of GBM patients; 2) high AUC values (>0.95) in 
ROC analyses of REMBRANDT and TCGA transcriptomic datasets; and 3) the availability 
of off-the shelf ELISA kits.
We assembled a collection of 84 plasma specimens from five different sources and subjected 
them to ELISA analyses for the four selected proteins. As we were unable to obtain GBM 
and normal plasma samples from the same source (and same collection procedure), we 
obtained each from multiple locations to help mitigate batch effects by performing analyses 
across data from multiple distinct sample sources, and different sources entirely in the 
training and test sets. All samples obtained were collected using the standard collection 
protocol for K2-EDTA (purple cap) blood. We subjected the samples to an independent 
training and validation format with each set being composed of age and gender matched 
GBM samples (21 training, 21 validation) and healthy samples (21 training, 21 validation) 
(Figures 5A–C and S3, Table S7). Following batch-normalization (standard score), the 
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training set was modeled using linear discriminant analysis (LDA). LDA characterizes 2 
classes as Gaussian densities of equal covariance using a linear combination of features. The 
performance of four GBMSig proteins in the identification of GBM class was assessed for 
validation set after locking down parameters. We observed 95.2% sensitivity and 95.2% 
specificity for the independent validation set (GBM=21, Healthy=21). ROC analyses of the 
training set exhibited an AUC of 0.99 while the validation set presented an AUC of 0.98 
(Figure 5A–C), highlighting significant differences in the abundance of these proteins in 
GBM patients versus normal controls. Power analysis of ELISA results also indicated good 
agreement between the effect size (>|0.6|) and the sampling method (power>0.8) (Figure 
S3E).
We then examined the changes in blood concentrations of the same four proteins (HMOX1, 
CD44, VCAM1, and BIGH3) for ten GBM patients prior to and after tumor resection. Blood 
samples were collected preoperatively and postoperatively at 24 hrs, 48 hrs, and ~10 days 
post-surgery (first post-operative visit). From ELISA analysis, we observed significant 
changes (p<0.05; ROC AUC of 0.83) in the blood concentrations of three proteins (HMOX1, 
CD44, and BIGH3), possibly reflecting the pathophysiological changes related to tumor 
resection (Figure 5D–E) within ten days of surgery. PCA analysis also revealed a separation 
of 52.1% on PC1 and 27% on PC2 for changes in the blood concentrations of HMOX1, 
CD44, and BIGH3 between 24hrs and 10days post-resection (Figure S4A–B, Table S8). 
However, since there was no endpoint to this study, it was not possible to relate the changes 
in the blood concentrations of these GBMSig proteins to the overall survival (OS) or 
progression-free-survival (PFS) of patients, which could be evaluated in future by 
undertaking longer and more frequent post-operative follow-ups.
Connections between the classifier and TGF-β responsiveness
Pathway analysis of GBMSig proteins using the KEGG database (Kanehisa and Goto, 2000) 
and GeneMANIA (www.genemania.org) reflected the role of GBMSig proteins in several 
established aspects of GBM biology, including: focal adhesion, ECM-receptor interaction, 
apoptosis, and the MAPK signaling pathway (Figures 2F and S2C). Additionally, co-
expression analysis of GBM tissue transcriptomics and proteomics data (Figure 3A,4A,4C) 
indicated that a number of proteins within the GBMSig classifier co-expressed with TGFBI 
(BIGH3)—a known TGF-β-inducible protein (Lauden et al., 2014; Nummela et al., 2012). 
This observation, along with a known role for TGF-β in cancer and GBM (Pickup et al., 
2013), highlighted possible TGF-β1 responsive network components operating within 
GBMSig classifier that could impact the modulation of other GBMSig proteins within the 
classifier. To determine whether GBMSig proteins could respond to TGF-β treatment and 
provide biological, mechanistic evidence for the classifier, we tested TGF-β1 responsiveness 
in the astrocytoma cell line U87MG through induction of C-terminal phosphorylation of 
SMAD2 (Figure 6A). Conversely, SMAD2 phosphorylation is diminished in the presence of 
TGF-β-inhibitor (SB 431542). Cell viability did not significantly change following 
treatment with TGF-β1 or its inhibitor relative to untreated cells (data not shown). Proteomic 
changes of GBMSig expressions following TGF-β/inhibitor treatment were evaluated by 
SRM assays. We observed 13 GBMSig proteins including TGFBI (BIGH3), which exhibited 
at least 1.5 fold higher expression following TGF-β treatment relative to cells treated with 
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TGF-β-inhibitor alone (Figure 6B and Table-S10). As basal TGF- β expression could 
contribute to expression of our GBMSig proteins, we found that cells pretreated with TGF-
β-inhibitor and subsequent TGF-β treatment modulated the expression of GBMSig proteins. 
There were four additional GBMSig proteins (CD47, MYOF, ABCA1, and CD44) that 
exhibited a positive enrichment (>1.2 fold over inhibitor treatment) for TGF-β treatment in 
comparison to TGF-β-inhibitor treatment alone. Details are presented in Table S10 and 
Figure S5. Changes in protein expression of SLC16A1, MRC2, SLC16A3, CD47, and CD97 
after TGFβ treatment relative to inhibitor treatment were confirmed by alternate method 
flow cytometry (Figure 6C). Results were consistent with the changes in protein expression 
observed by SRM. These observations highlight the modular responsiveness of a subset of 
GBMSig classifier with TGF-β signaling that was previously undescribed (Figure 6D).
TGF-β1 responsive GBMSig subset and tumor invasion
As a known inducer of epithelial to mesenchymal transition (EMT), TGF-β1 plays an 
important role in the local metastasis of tumor cells (Picon et al., 1998, Hoelzinger et al., 
2007). We determined if overexpression of TGFβ1-responsive transcripts from our GBMSig 
subset correlated with patient survival in the REMBRANDT data. Co-expression of these 
genes indeed correlated with poor patient survival (p<0.003, Log Rank, Mantel-Cox) (Figure 
6G). This correlation could be the result of several factors related to tumor development 
concurrent with the hypothesis that invasion is, in part, attributable to the action of TGF-β1. 
To further investigate the role of our TGF-β targets in this context, we inhibited the 
expressions of SLC16A1, MRC2, and CD47 through siRNA silencing and quantified 
differences in U87MG cell invasion. We confirmed effective siRNA knockdown by qPCR 
(Figure 6E) and flow cytometry (Figure S5B), and observed no significant impact on cell 
viability following knockdown (Figure 6F). siRNA or non-targeting siRNA treated cells 
were seeded in transwell chambers, and the degree of cell invasion was evaluated as the 
percentage of cells invaded compared to non-targeting siRNA treated cells. The resultant cell 
invasion from three independent experiments is presented in Figure 6G. The silencing of 
SLC16A1 and MRC2 caused 52.88% ± 9.70SEM, and 42.26% ±2.19SEM reduced cell 
invasion respectively—similar to knockdown of the known invasion-mediating protein CD47 
(57.74% ± 6.32SEM)-highlighting the role of these proteins in GBM invasion. We conclude 
that a subset of TGF-β responders play a crucial role in the migration and invasion of GBM 
cells, which in combination or alone may influence the clinical outcomes of GBM.
DISCUSSION
We formulated a systems strategy to develop GBMSig—a molecular signature for GBM 
composed of protein targets (table S9) originating from the cell-surface of diseased cells that 
provide excellent candidates that after shedding from the cell-surface can be detectable in 
the blood. We reasoned that cell-surface proteins would be the best candidates as they are 
most likely to be found in the blood due to their known role and function in disease 
associated cell-signaling processes (Li et al., 2013). The heterogeneity of GBM is well 
documented, and adds to the challenge of finding putative targets that can be reliably 
detected across heterogeneous tumors. For this reason, we wanted to enrich for putative 
targets that would likely be common to many GBM subtypes. Starting with four cell lines—
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two widely used cell lines of GBM, one established as having primary GBM cancer stem 
cell properties (e.g. expression of CD133), and a healthy neural stem cell line—we 
generated a list of putative targets by capturing and characterizing cell-surface proteins by 
mass spectrometry. Identification of cell-surface proteins by biotin labeling helped to enrich 
for proteins that are often difficult to detect because of their low abundance and 
hydrophobicity. By requiring all candidates to possess a known transmembrane domain, we 
likely eliminated many potential candidates. However, we feel our conservative approach 
greatly lessened the possibility of false positives. While reducing our target number from 
well over a thousand to 274, these targets were likely enriched for the properties most 
central to GBM blood biomarkers. We could detect that ten of the fourteen targets in the 
blood contained an N-terminal secretion signaling sequence (21 of 33 GBMSig targets) 
consistent with the properties our experimental design targeted.
We next relied upon existing microarray expression data to further enrich for candidate 
targets and explored how well they might work as classifiers. With a number of regulatory 
steps occurring between transcription and translation, we used the transcript array data as a 
filter to identify targets with appreciable RNA expression. Because the REMBRANDT and 
TCGA data sets were created for the purpose of better understanding heterogeneity across 
GBM and other tumor types, their small control sample size is not ideal for identifying the 
genes differentially expressed between tumor and normal samples. As we did not rely on the 
microarray expression data for generation of targets, but rather as a filter for the elimination 
of targets, the small control sample size was less of an issue. We further filtered our 
candidate list by removing differentially expressed genes that were also found in 
astrocytomas (148 samples) and oligodendrogliomas (67 samples), thus enhancing the 
specificity for GBM. Additionally, this integrative analysis ensured that the classifier was 
not based on expression of proteins that are the product of artifactual changes such as those 
that arise from cell culturing. Utilization of laboratory grown cell lines for the generation of 
candidates is consistent with the prior reports (Geiger et al., 2010). As GBM tumors are 
typically more aggressive and metastatic than other brain tumors, this filtering step may have 
selected for those genes specific to those functions. Previous work by our group used 
microarray data alone to identify gene networks that differ across astrocytoma grades (Wang 
et al., 2013). This previous work did not identify the TGF-β network and did not utilize 
anything resembling the filtering and proteomic data integration presented here, highlighting 
the differences achieved through an integrative omics approach. This filtering step may have 
enabled the identification of several TGF-β network proteins. In doing so, we may also have 
enriched for targets more likely to be in the blood, as metastatic mechanisms require 
signaling external to the primary tumor. This is supported by our analysis of the survival 
data, where co-expression of TGF-β responsive GBMSig genes correlated with poorer 
outcome (p<0.003, Log Rank, Mantel-Cox) (Figure 6H).
Following this filtering, we utilized the REMBRANDT and TCGA data for evaluating the 
performance of putative targets as classifiers. While the sensitivity (99.8%) and specificity 
(80%) were encouraging, with an MCC value of 0.87, the small control sample size limits 
the ability to determine the robustness of any classifier based on this evidence alone. 
However, we performed end-to-end experimental verification of the classifier and 
demonstrated that an integrated-omics approach was capable of producing a list of 
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candidates that performed well as classifiers across platforms (proteomics, transcriptomics, 
ELISA) and across experiments (REMBRANDT to TCGA).
With our GBMSig candidates that performed well as classifiers for both REMBRANDT and 
TCGA, we turned to identifying those candidates that could best be quantitatively and 
reproducibly detected in both tissue and blood. We were able to detect 14 of the 33 low-
abundant proteins in the blood and 21 of the 33 in brain tissue using the recently developed 
and sensitive approach of SRM. Further efforts to detect all proteins would likely have been 
productive as absence of detection is just as likely to be due to technical as it is biological 
reasons. Rather than optimize detection of all GBMSig targets, we chose to evaluate targets 
that could be reliably detected via established ELISA assays—the gold standard of clinical 
detection.
The vast majority of published biomarker candidates have failed to make it to the clinic 
(Micheel CM, 2012). A contributing factor to this high failure rate is the lack of properly 
designed experiments that contain truly independent training and test sets. We were unable 
to secure GBM and normal blood samples collected and processed by the same source. To 
circumvent this limitation, we acquired samples from five different sources, distributing 
samples from different sources into separate training and test sets. This approach makes it 
improbable, though not impossible, that our high sensitivity and specificity are the result of a 
batch effect. We have previously shown that multiple sources can be beneficial for the 
purposes of robustness and have the ability to help mitigate batch effects (Ma et al., 2014; 
Sung J, 2013; Wang et al., 2013). Even when mixing and matching samples in different 
configurations, we found our test to be robust, with comparable sensitivity and specificity 
(data not shown).
Our integrated omics approach also produced a list of candidates that are related to known 
characteristics of GBM. Many of the resulting targets had connections to TGF-β. We 
investigated the role of SLC16A1 and MRC2 in TGF-β responsiveness, showing that 
knockdown of these transcripts greatly reduced invasion. Recently, we have demonstrated 
that HMOX1 expression is associated with GBM stemness and invasion (Ghosh et al., 
2016). MRC2 was previously shown to correlate with TGF-β1 expression in hepatocellular 
carcinoma (Gai X, 2014). SLC16A1 has not previously been implicated in invasion nor 
linked with TGFβ1 signaling. We have provided experimental evidence in favor of modular 
roles for 17 GBMSig proteins (Table S10) in TGF-β signaling. How these proteins or other 
proteins in our GBMSig connected to TGFβ1 signaling function in relationship to each other 
is an outstanding question for future investigation.
Our ability to distinguish between blood from GBM patients and normal controls was 
robust, with high sensitivity (95.2%) and specificity (95.2%). This resulted in an AUC of 
0.99 for the training set and 0.98 for the validation set (Figure 5A–C), with great agreement 
between the effect size (>|0.6|) and the sampling method (power>0.8) (Figure S3E). 
Although we were not able to secure the control and the GBM samples from the same 
source, a high AUC value was observed that was unexpected. It is possible that this high 
agreement could be due to the novelty of the multi-omics, systems approach we used herein. 
Further application and interpretation of the results in the context of other cancers and/or 
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pathologies will be of interest moving forward. We attempted to demonstrate potential 
clinical utility in assaying changes in the blood concentrations of 3 of 4 GBMSig proteins 
following tumor resection (Figure 5D–E, S4A–B). Given the non-specificity of MRI 
imaging in evaluating the effectiveness of therapeutic options, performance of GBMSig in 
the longitudinal assessment of therapeutic changes might widen the scope for disease 
management in the future.
As our selection criteria for which targets to assay by ELISA were based on 1) SRM 
detection in the blood; 2) high AUC values (>0.95) in ROC analyses of transcriptomic data 
(Figure S2D–E); and 3) availability of commercial ELISA kits, we anticipate a canvasing of 
other targets for which reliable ELISA data could be generated would increase the options 
for development of a GBM-specific blood test—especially from the GBMSig extended 
candidate list. Targets with smaller variance or greater separation between case and control 
might also improve robustness or be the basis of distinguishing among diseases. Although 
our candidate selection process was designed to increase the likelihood of robust separation 
between GBM and lower grade brain tumors and healthy controls, performance of GBMSig 
in separating non-GBM cancer such as liver cancer is also encouraging (Figure S2G). 
However, it remains to be evaluated if other cancers or pathologies would exhibit similarities 
and/or differences in the pattern of GBMSig expression.
We have demonstrated the power of integrating large-scale transcriptomics data together 
with shotgun proteomics to identify proteins that can be quantitatively measured and used to 
distinguish between the blood of a GBM patient and a healthy individual. The TGF-β 
connection of several of our GBMSig targets lends itself to biological interpretation that is 
often lacking with statistically heavy approaches. Arguably, this is a product of how we 
integrated experimental proteomics data with carefully analyzed existing transcriptomics 
data. Translating what we have learned here to a clinical application requires significantly 
more work, but many of the principles and systems applications demonstrated here can 
enable future efforts. We have an excellent candidate list of GBM biomarkers with which to 
move forward into the validation stage. We believe this general approach will be applicable 
to generating diagnostic blood protein panels for virtually any disease where the phenotype 
distinctions between normal and disease are clear.
STAR*METHODS
Detailed methods are provided in the online version of this paper and include the followings:
Contact for Reagent and Resource Sharing
Further information and requests may be directed to Leroy Hood at the Institute for Systems 
Biology (lhood@systemsbiology.org).
Experimental Model and Subject Details
Human Studies—IRB committee approvals and informed consent were obtained from all 
patients. The inclusion criteria for GBM patients were: 1) diagnosed as GBM based on 
clinical assessment, 2) plasma samples (collected in K2-EDTA tubes) were obtained prior to 
surgical removal of tumor mass, 3) age was >15 yrs., 4) subject was not suffering from any 
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other cancer, 5) GBM patients received standard care of treatment, 6) both male and female 
subjects were included, 7) plasma samples were archived, labeled and fresh frozen. Age and 
gender of the subjects are provided in table S7. Healthy controls were purchased from 
Bioreclamation (Healthy-source-1 and Healthy-source-2A), and Proteogenex (Healthy-
source-2) with the following inclusion criteria 1) subjects were healthy with no known 
chronic diseases, 2) no previous history of cancer, 3) age and gender matched with that of 
GBM subjects, and 4) plasma samples were archived, labeled and fresh frozen. GBM 
plasmas for the training set and longitudinal set (collected pre-operatively and post-
operatively at 24hrs, 48hrs, and ~10 days) were collected from Swedish Medical Center, 
Seattle, and the validation set were collected from California Pacific Medical Center 
Research Institute (CPMCRI), San Francisco. Equal number of GBM (21 subjects) and 
healthy (21 subjects) blood plasma specimens was selected for training data set. Power 
analysis (>0.8) justified the inclusion of similar number of GBM (21 subjects) and healthy 
(21 subjects) blood plasma samples for the validation set. For power analysis, please refer to 
python codes in Data S1 and the figure S3E.
Cell Culture—The human GBM cell lines U87MG and T98 obtained from ATCC were 
grown in DMEM high glucose culture medium supplemented with 10%FBS and Pen Strep. 
Neural stem cells (NSCs) from Millipore and cancer stem cells (CSCs) from Celprogen were 
grown according to suppliers’ specifications.
Methods Detail
Cell-Surface Labeling and Mass Spectrometry—EZ-Link-Sulfo-NHS-SS-biotin 
(Pierce) kit was used to surface label U87, T98, neural stem cell (Millipore) and cancer stem 
cell (Celprogen) according to manufacturer instruction. Biotinylated cell surface proteins 
were affinity-purified on neutravidin beads (supplied with the kit). After stripping off non-
specifically bound proteins by several rounds of washing with the lysis buffer (supplied with 
the kit) followed by water wash (to remove excess reagents), labeled proteins were 
selectively eluted with DTT at elevated temperature to ensure higher recovery of bound 
proteins. Eluted proteins were concentrated onto 10kDa micro ultrafiltration unit and 
reduced in the same ultrafiltration unit with 10mM TCEP for 60 min at 37°C. Excess TCEP 
was neutralized by washing the membrane with equal volume of 100mM ammonium 
bicarbonate followed by alkylation with 55mM iodoacetamide for 1hr in dark. Excess 
alkylating agent was quenched with molar equivalent of TCEP by incubating at RT for 
15min followed by washing the membrane several times with digestion buffer containing 
50mM ammonium bicarbonate, 10% TFE and 1mM CaCl2. Proteins were digested on 
membrane serially with trypsin for 12hrs at 37°C with 1:25 enzyme-to-protein ratio and Glu 
C for 6 hrs with 1:50 enzyme-to-protein ratio at RT in dark, respectively. Enzymatic 
digestion was quenched by adding 20μl of 0.2%FA, and digested materials were collected by 
centrifugation. Peptides were lyophilized and re-dissolved in 1% ACN, 0.1% FA for mass 
spec analysis using a Thermo Electron Orbitrap mass spectrometer (LTQ ORBITRAP) 
equipped with an electrospray ionization source in line with an Agilent HP1100 liquid 
chromatography system. Peptide digests were enriched onto a 2cm pre-column packed in-
house with 200Å Magic C18AQ resin and separated using a ProteoPep II 75μm i.d. × 10cm 
analytical column on 160 min ACN gradient as follows: 2%B (Buffer B-100%ACN/
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0.1%FA) for 5min, 2–10%B for 20min, 10–25%B for 65min, 25–40%B for 20min, 40–
60%B for 15min, 60–100%B for 10min, and held at 100%B for 13 min followed by 
equilibration of column for 17min with buffer A (Buffer A-2%ACN/0.1%FA). Pump flow 
rate was maintained constantly at 0.350μl/min. Mass spectrometer was operated in positive 
data-dependent acquisition mode with 1 S MS scan (m/z 300–1800; 30,000 resolution) 
followed by 9 MS/MS events for peptides with charge states between +2 and +4. Dynamic 
exclusion was set for 60 sec. Each isolate was run three times. After data acquisition, 
Xcalibur (Thermo) raw data were converted to mzXML format using ReAdW profile and 
default parameters. Peptide assignments were done using the GPM (www.thegpm.org).
Brain Tissue Processing—Brain tissues were homogenized in tissue lysis buffer (TLB) 
composed of 100mM n-octyl-glucoside, 1% NP-40, 150mM NaCl, 1mM PMSF, 2mM 
sodium orthovanadate and 50mM sodium fluoride in 50mM TEAB, pH8.0. Tissue 
homogenate was clarified by centrifugation at 10,000×g for 10 min and the supernatant 
containing the proteins of interest was preserved at −80°C till further use. For SRM analysis, 
tissues were reduced, alkylated, and then digested with trypsin and Glu C o/n in dark. 
Digestion reaction was quenched with TFA, and peptides were lyophilized, C18 purified and 
solubilized in 1%ACN/0.1% FA for SRM analysis.
GBM Subtyping—Total RNA was isolated from tissue samples with Triazol, and then 
cleaned with RNeasy MinElute Cleanup Kit. 1 μg of total RNA was used to generate 100 μl 
of cDNA using the High Capacity cDNA Reverse Transcription Kit. Real-time PCR of 
MGMT was performed on the ABI PRISM 7900 HT detection system using 33 Taqman 
probes (Phillips et al., 2006) and Taqman reagents under default conditions: 95°C for 10 
minutes, 40 cycles of 95°C for 15 seconds, and 60°C for 1 minute with human beta-
glucuronidase (hGUS) as endogenous control. All assays were done in triplicate. The 
expression level of each gene (Δct) for each tissue sample is calculated compared to the 
hGUS expression level using the formula 2−(Ct value of gene − Ct value of hGUS). qRT-PCR was 
performed for 4 GBM tissue samples (Table S5) for the 33 gene panel as described by 
Phillips et al. For each gene we obtained the average Δct (μ) and standard deviation (σ). For 
each tissue sample we calculate standard scores (z) for all 33 genes as follows: zg = Δctg − 
μ/σg, where g ∈ 33 gene panel. Three components: 1) Mesenchymal (M), 2) Proliferative (P) 
and 3) Proneuronal (N) expressions were calculated by taking the average of z scores of all 
genes belonging to the corresponding component.
M = μ(zg), where g ∈ component Mesenchymal
P = μ(zg), where g ∈ component Proliferative
N = μ(zg), where g ∈ component Proneuronal
Finally, the subtype is determined using the following reference range.
Mesenchymal M > P + 0.2, M > N + 0.2
Proliferative P > M + 0.2, P > N + 0.2
Proneuronal N > M + 0.2, N > P + 0.2
Prolifmes P > N + 0.2, M > N + 0.2, |P-M| < 0.2
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Mesneuronal M > P + 0.2, N > P + 0.2, |N-M| < 0.2
Prolifneuronal P > M + 0.2, N > M + 0.2, |N-P| < 0.2
SRM Assay Development and Analysis—Agilent Triple Quadrupole equipped with 
ChipCube nanoelectrospray ionization source in line with 1200 nanoFlow HPLC system was 
employed for SRM assay development and subsequent analysis. Cell surface peptide library 
developed through prior high-resolution shotgun analysis (described earlier in shotgun mass 
spectrometry section) provided the foundation to synthesize C-terminally labeled (13C15N) 
surrogate peptides for 33 GBMSig. Collision energy (CE) values for each peptide bond were 
optimized using the Mass Hunter Optimizer for Peptides Software (Agilent Technologies). 
All combinations of +2, +3 and +4 of Q1 and +1 and +2 of Q3 ion pair (only y-series of 
ions) of each peptide were undertaken for CE optimization. The top 4–5 transition pairs 
(Q1/Q3) and corresponding CE values that ensured maximum signal intensity of SRM trace 
was employed for quantitation. To develop dynamic-SRM (d-SRM) assay, retention time of 
each peptide was determined a priori by spiking C-terminally labeled (13C15N) surrogate 
peptides in presence of corresponding biological isolates (cell, tissue or serum). The 
abundance of endogenous peptides was assessed from co-eluting surrogate peptides 
(13C15N) which ensured precise quantification, All SRM acquisition method was run with 
standard parameters viz. capillary voltage 1700–2100, a sheath gas flow of 11 L/min at a 
temperature of 380°C, a drying gas flow of 15 L/min at a temp of 150°C, nebulizer gas flow 
at 30psi, the fragmentor voltage at 380 V, the cell accelerator voltage at 7 V, an MS 
operating pressure of 5×105 Torr and Q1/Q3 set to operate in unit resolution.
All samples were loaded onto HPLC chip comprising of an enrichment column (160nL or 
500nL) and a 150mm analytical C18 column. For plasma SRM analysis, 500nL enrichment 
column was used and peptides were eluted (with nanopump flow of 0.3μl/min) over step 
gradients as follows: 4%B for 2min, 25%B for 53min and maintained for 5min, 47%B for 
12min and maintained for 10 min followed by column washing for 10 min at 0.5μl/min and 
equilibration for 11min at 0.3μl/min flow rate.
Plasma Depletion—All plasma samples were immunodepleted using a C10/10 column 
packed in-house with 6ml bulk Seppro IgY14 matrix capable of depleting top 14 abundant 
proteins from human plasma prior to SRM mass spectrometry. Flow through fraction was 
concentrated onto 10kDa micro ultrafiltration unit and reduced in the same ultrafiltration 
unit with 10mM TCEP for 60 min at 370C. Excess TCEP was neutralized by washing the 
membrane with equal volume of 100mM ammonium bicarbonate followed by alkylation 
with 55mM iodoacetamide for 1hr in dark. Excess alkylating agent was quenched with 
molar equivalent of TCEP and incubating at RT for 15min followed by washing the 
membrane several times with digestion buffer containing 50mM ammonium bicarbonate, 
10% TFE and 1mM CaCl2. Proteins were digested on membrane serially with trypsin for 
12hrs at 37°C with 1:25 enzyme-to-protein ratio and Glu C for 6 hrs with 1:50 enzyme-to-
protein ratio at RT in dark respectively. Enzymatic digestion was quenched by adding 20μl 
of 0.2%FA and digested materials were collected by centrifugation. Peptides were 
lyophilized and re-dissolved in 1% ACN, 0.1% FA. After C18 clarification, each specimen 
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was spiked with heavy (13C15N K/R) synthetic GBMSig peptides for SRM mass 
spectrometry analysis.
Flow Cytometry—The following antibodies were used in the study: SLC16A1, MRC2, 
SLC16A3, CD47, and CD97. Cells were harvested after washing with ice-cold washing 
buffer (PBS/0.1% sodium azide) and incubated with primary antibody in antibody 
incubation buffer (1% BSA in PBS/0.1% sodium azide) for 1hr on ice. After washing the 
cell pellets with washing buffer, cells were incubated with FITC conjugated anti-mouse or 
PE conjugated anti-rabbit for 30 min on ice at 1:100 or 1:200 dilutions (prepared in antibody 
incubation buffer) respectively. Unbound conjugates were removed by washing with the 
washing buffer. Flow cytometry analysis was performed on FACSCalibur (BD Biosciences). 
The mean fluorescence intensity (MFI) of FITC or PE-positive cells (three replicate runs) 
was measured in comparison to respective isotype controls and the data were analyzed using 
FlowJo.
Western Blotting—Total proteins from U87 cells treated with TGF-β or its inhibitor were 
lysed by sonication in TLB, composed of 100mM n-octyl-glucoside, 1% NP-40, 150mM 
NaCl, 1mM PMSF, 2mM sodium orthovanadate and 50mM sodium fluoride in 50mM 
TEAB, pH8.0. After protein estimation with Pierce 660, equal amount of protein (8μg) from 
each isolate was separated by electrophoresis on Mini-Protean TGX 4–15% precast gel 
(Biorad) and transferred to nitrocellulose membrane using a semi-dry blotting (Biorad) 
apparatus. The membrane was blocked in TBS containing 3% FBS for 30min/RT and 
incubated with anti-SMAD2 or C-terminally phosphorylated SMAD2 at 1:1,500 dilution or 
anti-GAPDH at 1:15,000 dilution O/N at 40C. After washing the membrane with TBS/
0.1%T-20, membrane was incubated with appropriate HRP-conjugated secondary antibody. 
The Fisher SuperSignal West Femto Chemiluminescent Substrate was used for detection. 
The blot was visualized using Biorad gel documentation unit.
siRNA Treatment and qPCR Analysis—U87 cells (one million) maintained in DMEM 
high glucose culture medium supplemented with 10%FBS and penicillin-streptomycin were 
plated in a 10 cm dish. 24 hours after seeding, cells were washed with HBSS prior to 
reducing FBS to 0.2% in DMEM for siRNA treatment. ON-TARGETplus-SMARTpool 
siRNAs for SLC16A1, MRC2, CD47 and ON TARGETplus Non-targeting pool were used 
in the study. siRNAs were added at a 2:1 ratio of Dharmafect to siRNA for a final 
concentration of 40 nM per the manufacturer instructions. For Quantitative Real-time PCR 
(qRT-PCR) analysis of target gene inhibition, RNA was isolated per the manufacturer 
instructions using Qiagen RNeasy Kit. RNA was converted to cDNA using Applied 
Biosystems High Capacity cDNA Reverse Transcription Kit, per manufacturer instructions. 
qRT-PCR was performed on an ABI 7900 HT 384-well format using Power Syber Green. 
For the following genes, primers were designed using the online tools provided by 
Integrated DNA technologies (IDT): HPRT1 forward 5′-TGCTGAGGATTTGGAAAGGG, 
HPRT1 reverse 5′-ACAGAGGGCTACAATGTGATG, MRC2 forward 5′-
ACCAGCAACATATCCAAGCC, MRC2 reverse 5′-GAGTTTCCCTGGATGGTGTAG, 
SLC16A1 forward 5′-GTGGCTTGATTGCAGCTTC, SLC16A1 reverse 5′-
TGGTCGCCTCTTGTAGAAATAC, CD47 forward 5′-
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TGGTATGGATGAGAAAACAATTGC, CD47 reverse 5′-
GTCACAATTAAACCAAGGCCAG. PCR pairs were designed to generate amplicons 
between 90–130 base-pairs and pre-evaluated for a dissociation curve.
Cell Invasion Assay—Quantitative cell invasion assay was performed for U87MG cells 
using the invasion kit according to manufacturer’s instructions. Percentage of siRNA treated 
cells invaded in respect to non-targeting RNA treated cells were assessed from three 
independent experiments with three replicates each time.
Quantification and Statistical Analysis
Data Normalization—All numerical raw data were normalized to standard score (Z-score) 
using the formula,  is the raw value and μ is the mean of the population, σ is the 
standard deviation of the population.
SRM Quantification—SRM data were analyzed using Skyline (Bereman et al., 2012). 
SRM traces were integrated by default peak integration method and processed with 
Savitzky-Golay smoothing algorithm as described in Skyline. For precise identification and 
quantification of targets, each SRM trace was manually inspected for three- Q1/Q3 transition 
pairs with retention time determined empirically in prior runs. Peptide peak ratios 
(endogenous: surrogate) from three independent runs of each sample were averaged and 
expressed per μl of neat plasma or per μg of total protein as in the case of brain tissue 
homogenates. Final data were expressed as standard score (Z score).
Development of GBMSig—The human tissue expression array of GBM (N=228 
subjects) and non-tumor (N=16 subjects) isolates in REMBRANDT [https://
gdoc.georgetown.edu/gdoc/] were used as training datasets to distinguish differentially 
expressed cell-surface-transmembrane proteins as predicted using TMHMM algorithm 
(http://www.cbs.dtu.dk/services/TMHMM/). We employed R: Bioconductor 
(www.bioconductor.org) packages “affy” and “limma” for gene expression analysis. Cell 
surface proteins differentially expressed between GBM and non-tumor with log2-fold 
change >2X and FDR <0.05 was undertaken for further analysis. To identify GBM enriched 
expression, astrocytoma (N=148 subjects) and oligodendroma (N=67 subjects) tissue arrays 
in the same compendium were also assessed. Predictive accuracy of GBMSig was evaluated 
using independent transcriptome dataset in TCGA (547 GBM tumors and 10 non-tumor 
brain controls).
Statistical Analysis and Modeling—True performance of GBMSig classifier was 
evaluated through SVM. For SVM modeling, tissue transcriptomics data in REMBRANDT 
were used as training set. Using R package CvTools, REMBRANDT data were splitted 
(K=10) into training and validation sets. To achieve, the highest level of accuracy, we 
performed autotuning of the hyperparameters and selected the best value for gamma and 
cost for subsequent modeling as follows:
gamma cost error dispersion
1.00E–06 0.1 0.072727 0.05749596
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1.00E–05 0.1 0.072727 0.05749596
1.00E–04 0.1 0.072727 0.05749596
1.00E–03 0.1 0.072727 0.05749596
1.00E–02 0.1 0.072727 0.05749596
1.00E–01 0.1 0.072727 0.05749596
1.00E–06 1 0.072727 0.05749596
1.00E–05 1 0.072727 0.05749596
1.00E–04 1 0.072727 0.05749596
1.00E–03 1 0.072727 0.05749596
1.00E–02 1 0.072727 0.05749596
1.00E–01 1 0.022727 0.03214122
1.00E–06 10 0.072727 0.05749596
1.00E–05 10 0.072727 0.05749596
1.00E–04 10 0.072727 0.05749596
1.00E–03 10 0.068182 0.05769525
1.00E–02 10 0.013636 0.03067948
1.00E–01 10 0.009091 0.01916532
Best parameters: gamma=0.1 and cost=10.
SVM modeling was performed using the R package e1021. Minimization of the error 
function was calculated using the following formula: , constraints=yi(wT 
θ(xi)+b) ≥1− ζi and ζi ≥ 0, = 1, …. N;kernel θ=exp(−γ|xi−xj|; C=capacity constant, w= 
vector of coefficients, b= constant, ζi= parameters for handling inseparable data, y= class 
labels,xi=independent variables, and θ=kernel. To train the SVM model (C-classification) 
we used radial kernel, gamma=0.1, and cost=10 (as determined following autotuning of the 
hyperparameters). To assess the quality of the training results, accuracy of the model was 
calculated from 100fold cross validation, which revealed mean accuracy of 98.63%. Once 
the model was trained we evaluated the sensitivity, specificity, positive predictive value 
(PPV) and negative predictive value (NPV) of the classifier for independent validation set in 
TCGA: Sensitivity= TP/|P|; Specificity= TN/|N|; Precision= TP/TP+FP; PPV= TP/(TP+FP); 
NPV= TN/(TN+FN); where TP= True positive predicted by the model, |P|= Total Positive, 
TN= True negative predicted by the model, |N|= Total Negative, FP= False positive i.e. 
healthy instances predicted as GBM, FN= False negative i.e. true GBM instances predicted 
as healthy.
Power Analysis—To achieve empirical validity, power analysis was performed. Power 
analysis of ELISA data were performed using statsmodel library in python with alpha=0.05; 
effect size for ELISA data was calculated using Cohen’s d, where
For detailed analysis, please refer to the python code provided as Data S1.
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Linear Discriminant Analysis (LDA)—A LDA method was developed to evaluate the 
performance of a subset of GBMSig (HMOX1, CD44, BIGH3, and VCAM1) proteins as 
blood classifier. ELISA Training data set (GBM plasmas= 21, and Healthy plasmas= 21) 
was modelled using LDA from the scikit-learn python package and the performance of the 
classifier were predicted for the validation set (GBM plasmas= 21, and Healthy plasmas= 
21). For detailed analysis, please refer to the python codes provided as Data S1.
Receiver Operating Characteristic (ROC) Curve Analysis—Diagnostic 
performance and accuracy of the classifier in separating GBM and normal controls were 
assessed through ROC analysis as described in Medcalc. Sensitivity and specificity for a 
given GBMSig is calculated as: Sensitivity  and specificity ; where a=True 
positive =(TP), b= False Negative (FN), c= False Positive (FP), and d= True Negative (TN).
Data and Software Availability
Python code used in the study is provided as Data S1.
Proteomics data for individual cell lines and replicate analyses are available from 
www.thegpm.org. Please refer to key resources table for unique GPM identification numbers 
that are required to access the data.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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• Cell-surface proteomics of four cell lines relevant in glioblastoma.
• Development of a 33-cell-surface-protein signature for glioblastoma.
• Association of a subset of the signature with TGF-β signaling and cancer 
invasion.
• Potential of a subset of GBMSig proteins as blood biomarkers.
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Description of the rationale and accompanying filtering steps applied to the initial list of 
proteins identified through sulfo-NHS-SS-biotin tagging of intact cells from four cell lines: 
U87MG, T98, CD133+ cancer stem cells and neural stem cells. From the 1480 candidate 
proteins, 274 contained transmembrane domains. Corresponding probes were found for 202 
targets in the REMBRANDT data set containing 228 GBM and 16 non-tumor brain tissue 
specimens. Genes found to be commonly expressed in oligodendrogliomas and astrocytomas 
were then removed to enrich for GBM-specific targets. This resulted in 33 targets identified 
as GBMSig. SRM mass spectrometry assays were developed for each of these targets. 
Twenty-one of the 33 GBMSig proteins could be detected across 4 GBM and 2 non-tumor 
brain specimens. Fourteen of the 33 proteins were also detected in the blood (following 
immunodepletion of the top 14 abundant blood proteins). Each of the 33 targets was 
evaluated as a classifier on 547 GBM and 10 control samples from TCGA. Four targets were 
selected based on the robustness as a classifier, ability to be detected in the blood and 
availability of a commercial ELISA assay.
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Compositional analysis of cell-surface proteins (CSPs) from three independent runs by high 
resolution mass spectrometry in (A) U87MG, (B) T98, (C) cancer stem cell (Celprogen), 
and (D) neural stem cell (Millipore). Proteins with log(e)=−3 score (GPM) were considered 
valid. Numerical data represents proteins identified in each isolates. E) Functional analyses 
of cell-surface proteins with transmembrane domains identified in the study highlight the 
enrichment of those biological processes that are known to be associated with cell-surface 
activities. Fold enrichment is presented as a ratio of number of cell-surface transmembrane 
proteins identified for a given biological process relative to whole genome annotations with 
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indicated p values. F) Cartoon diagram (KEGG) showing the identification (highlighted in 
orange) of those proteins associated with cell migration and invasion.
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Cell-surface proteins with transmembrane domains identified from shotgun proteomics were 
evaluated for their differential expressions using transcriptome compendiums of 
REMBRANDT and TCGA. A) The differential expression of 202 cell-surface 
transmembrane proteins in GBM tissues (N=228) relative to non-tumor brain specimens 
(N=16) of REMBRANDT transcriptome compendium. Expression values for these 
transcripts were log2 transformed, and a minimum of two-fold average expression change 
(FDR<0.05) between tumor and non-tumor brain tissues was used as cut-off for significance. 
Clustering reflects the directionality of cell-surface transmembrane transcript expression 
among GBM and controls. Non-tumor brain specimens are highlighted in yellow at the 
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bottom. B) majority of the cell-surface proteins with transmembrane domains mapped to 
REMBRANDT transcripts were discarded due to common expressions in non-GBM 
diseases such as astrocytoma (N=148) and oligodendroma (N=67 tumors). Shown are 33 
cell-surface transmembrane proteins that were subsequently tested for the development of 
GBMSig classifier. Each column of the heatmap is presented as the average log2 [tumor/
non-tumor] ratios. CNT is non-tumor brain, AST is astrocytoma, and OLI is oligodendroma. 
C) Principal component analysis (PCA) of REMBRANDT GBM transcriptome arrays with 
GBMSig (n=33). Red dots represent non-tumor isolates and grey ones are GBM. Two 
principal components can explain 43% of the variability. D) Principal component analysis 
(PCA) of independent TCGA GBM transcriptome datasets composed of 547 GBM 
specimens and 10 non-tumor brain controls with GBMSig (n=33). Two principal 
components can explain 48% of the variability. Red dots represent non-tumor isolates and 
grey ones are GBM. E) ROC analysis of REMBRANDT tissue arrays for individual 
GBMSig proteins. Specificity (%) and Sensitivity (%) values of individual GBMSig were 
plotted on X and Y axis respectively. Standard error of AUC was calculated using the 
method described by DeLong et al. Orange color represents significance level P (Area=0.5) 
<0.0001 while gray color represents P>0.01.Detailed analysis is provided in table S2. F) 
ROC analysis of independent TCGA tissue arrays (GBM=547 subjects, NonTumor=10 
subjects) for individual GBMSig proteins. Specificity (%) and Sensitivity (%) values of 
individual GBMSig were plotted on X and Y axis respectively. Standard error of AUC was 
calculated using the approach described by DeLong. The analysis revealed high degree of 
specificities and sensitivities in discriminating GBM populations from controls with 
significance level P (Area=0.5) <0.0001. Detailed analysis is provided in Table S2.
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Figure 4. Proteomic verification of GBMSig expression in GBM tissues by SRM mass 
spectrometry
A) Equal quantities of tissue homogenates from tumor (n=4) and non-tumor isolates (n=2) 
were enzymatically digested, C18 clarified, and spiked with surrogate peptides labeled C-
terminally with 13C15N K/R for SRM analysis. Ratios of endogenous and surrogate peptides 
were centroided and presented as Z-score in the heatmap. A subset of GBMSig (*) was also 
observed to be circulated in the blood plasma. Co-expression of several GBMSig proteins 
with BIGH3 (TGFBI) - a known TGFβ-inducible protein might be indicative of the presence 
of additional TGF-β responsive elements operating within GBMSig. Based on GBMSig 
expressions, GBM and non-tumor tissues can be arranged into groups as revealed through 
Spemann rank clustering. B) PCA analyses of GBMSig proteins as quantified by SRM mass 
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spectrometry can distinguish GBM from non-tumor brain specimens with first two 
components explaining 70.78% of variability, highlighting the robustness of GBMSig in 
separating GBM from controls with high efficiency at both transcriptome and proteome 
levels. C) Contributions of each GBMSig protein onto respective principal components. 
Expected average contributions on PC1 and PC2 are denoted by a red and blue line 
respectively. D) Subtyping of GBM 1–4 tissues were performed using qPCR for 33 genes as 
described (Phillips et al., 2006). Accordingly, GBM-1 is assigned as prolifimes, GBM-2 as 
mesenchymal, GBM-3 as proliferative, and GBM-4 as proneuronal. This subtyping allowed 
us to explain the heterogeneities in GBMSig expression observed from proteomic analysis. 
Subtype expression data (qPCR) are provided in table S5.
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Blood Diagnostic potentials of four GBMSig proteins. A) four GBMSig proteins viz. CD44, 
VCAM1, HMOX1, and BIGH3 (TGFBI) were evaluated by ELISA assays using 84 plasma 
samples obtained from 3 different locations. Despite different sites of collection, both 
training set and validation set revealed statistically significant differences between GBM 
(GBM-Src-1 and GBM-Src-2) and healthy controls(H-Src-1,H-Src-2, and H-Src-2A). p 
values are two tailed and welch corrected. B) ELISA results from training set were modelled 
using Linear Discriminant Analysis (LDA). The training set created a classifier with a 
scaling factor of (0.72, −1.1, −.05. −.68) for HMOX1, BIGH3 (TGFBI), VCAM1 and CD44 
respectively. The decision boundary coefficients are at (−1.83, 1.83) with an intercept of 
−2.38. Performance of these four GBMSig proteins was assessed for an independent 
validation set (GBM=21, Healthy=21). We observed 95.23% sensitivity and 95.2% 
specificity with 95.2% accuracy for the independent validation set. Dec. Boundary is 
Decision Boundary. C) Shown here is the ROC analysis of validation set that exhibited an 
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AUC of 0.98, highlighting robust discerning ability of GBMSig proteins as attractive 
candidates. D) MRI images showing the changes in tumor volume before (A) and after 
resection (B) for ten GBM patients recruited prospectively for the blood analysis. E) Boxplot 
showing the changes in the plasma values for 4 GBMSig proteins at 24hrs, 48hrs, and 
10days (~) post-resection as measured through ELISA assays. Data were normalized to 
preoperative condition for individual patient. Y-axis represents GBMSig values in ng/unit of 
total protein. Black dots represent each patient and ‘*’ indicates p<0.05.
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Figure 6. Association of GBMSig proteins with TGF-β1 signaling network
A) U87MG cells were treated with TGF-β1 or its inhibitor in presence or absence of FCS to 
evaluate i) endogenous c-terminally phosphorylated SMAD2 (lane-1), ii) the ability of TGF-
β1 to phosphorylate SMAD2 (lane-2), iii) the ability of TGF-β1-inhibitor to inhibit SMAD2 
phosphorylation when cells were grown in normal media (lane-3), iv) the ability of TGF-β1 
to induce SMAD2 phosphorylation in cells grown earlier in presence of TGF-β1-inhibitor 
(lane-4), and v) the level of SMAD2 phosphorylation on prolong TGF-β1 exposure (50hrs) 
when cells were grown in normal growth media (lane-5). The results demonstrated i) the 
ability of TGF-β1-inhibitor in inhibiting c-terminal phosphorylation of SMAD2 (lane-3) 
similar to when cells were grown in serum-free media (lane-1&2) and ii) reversible nature of 
c-terminal phosphorylation inhibition of SMAD2 that could be reversed with TGF-β1 
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treatment (lane-3&4). GAPDH was used as loading controls. B) SRM analysis of TGF-β or 
its inhibitor treated U87MG cell lines revealed responsiveness of a subset of GBMSig 
proteins towards TGF-β signaling. Complete list of GBMSig proteins detected in various 
biospecimens and the responsiveness of these proteins towards TGF-β/Inhibitor is provided 
in the supplementary tables S9 and S10 respectively. Data from four replicates SRM 
analyses were centroided and presented as Z-score. C) flow cytometry analysis of a subset of 
GBMSig proteins following TGFβ/Inhibitor treatment. Percentage of changes in mean 
fluorescence intensity (MFI) was measured from treating U87MG cell lines with TGFβ 
relative to its inhibitor. Data represent means ± S.D. from four-replicate analyses. D) 
Network relationship (drawn using Cystoscape) between GBMSig proteins, which are 
presented as nodes. These nodes are connected through edges based on known pathways and 
co-expression. Color of the nodes is controlled by fold changes in expression of GBMSig 
proteins on TGFβ treatment. Grey colored nodes represent extended relationship with 
GBMSig proteins. E) qPCR analysis of siRNA mediated interference of a subset of TGFβ 
responsive GBMSig elements viz. MRC2, SLC16A1, and CD47 genes in U87MG cells. 
Results from three independent siRNA treatments (30hrs) were averaged (error bars 
represent S.D.) and presented as CT ratios normalized to HPRT housekeeping gene. PARP1 
expression was used as non-targeted control. F) Calcein AM assay indicates no significant 
changes in cell growth and proliferation following siRNA mediated inhibition of SLC16A1, 
MRC2, and CD47 in U87 cell lines. Data represent means ± S.D. from five replicate 
analyses. G) siRNA treated U87 cells were allowed to migrate towards TGF-β1 gradient 
through basement membrane (Cell Biolabs Inc.). Invaded cells were analyzed through 
colorimetric assay. Results from three independent experiments were averaged and 
normalized to non-targeting siRNA pools (scrambled). As evident, loss of cell migration 
following siRNA mediated inhibition of SLC16A1 and MRC2 is similar to that of known 
invasive marker CD47. Data represent means ± S.D. from three replicate analyses. H) A 
panel of TGF-β responsive GBMSig (CA12, MRC2, TNC, CD44, SLC16A1, S100A10, 
ITGA7, CLCCI, and SLC16A3) highlights poor survival (p<0.003, log rank, Mantel-Cox) 
among GBM patients (class 2) when overexpressed relative to GBM patients where these 
genes were low expressed (class 1).
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